Net Clinical Benefit of Antithrombotic Therapy in Patients With Atrial Fibrillation and Chronic Kidney Disease

Integrating real-time clinical information to provide estimates of net clinical benefit of antithrombotic therapy for patients with atrial fibrillation.

BACKGROUND Guidelines for anticoagulant therapy in patients with atrial fibrillation are based on stroke risk as calculated by either the CHADS2 or the CHA2DS2VASc scores and do not integrate bleeding risk in an explicit, quantitative manner. Our objective was to quantify the net clinical benefit resulting from improved decision making about antithrombotic therapy. METHODS AND RESULTS This st...

Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation

Background—Known risk factors for bleeding during anticoagulant treatment are largely the same as those predicting thromboembolic events in patients with atrial fibrillation (AF). Our objective was to investigate how to maximize the likelihood of avoiding both stroke and bleeding. Methods and Results—All 182 678 subjects with atrial fibrillation in the Swedish Hospital Discharge Register were s...

Net clinical benefit of warfarin: extending the reach of antithrombotic therapy for atrial fibrillation.

The Net Clinical Benefit of Warfarin : Extending the Reach of Antithrombotic Therapy for Atrial Fibrillation

Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation.

BACKGROUND Little is known about the net clinical benefit of warfarin therapy in elderly patients with atrial fibrillation. METHODS AND RESULTS We studied 2339 Chinese patients with nonvalvular atrial fibrillation aged≥80 years: 1805 with no antithrombotic therapy and 534 on warfarin therapy. Patients were stratified according to their CHA2DS2-VASc and HAS-BLED score. The primary end point wa...